Behavioural evidence for central D-2 dopamine receptor agonistic effect by some 2-(fluorohydroxyphenyl)ethylamines

Area of Science:

• Neuropharmacology
• Dopamine receptor research

Background:

• Central dopamine D-2 receptors play a crucial role in various physiological functions.
• Understanding the selective modulation of these receptors is key to developing new therapeutic agents.

Purpose of the Study:

• To investigate the central D-2 dopamine receptor activity of novel phenylethylamine derivatives: FDA 24, FDA 27F, and FDA 40.
• To evaluate the in vivo effects of these compounds on behaviors indicative of dopamine receptor stimulation.

Main Methods:

• Intraperitoneal administration of FDA 24, FDA 27F, and FDA 40 to adult male rats.
• Observation and quantification of stretching and yawning (SY) syndrome and penile erection (PE).
• Assessment of compound effects using selective D-2 dopamine receptor antagonists (sulpiride and domperidone).

Main Results:

• FDA 27F and FDA 40 induced SY and potentiated PE, with FDA 40 being the most potent.
• Both compounds demonstrated dose-dependent effects typical of central D-2 dopamine receptor agonism.
• Pretreatment with sulpiride, a central D-2 antagonist, inhibited these effects, while domperidone did not.

Conclusions:

• FDA 27F and FDA 40 effectively cross the blood-brain barrier and act as agonists at central D-2 dopamine receptors.
• The PE and SY tests are validated as sensitive bioassays for studying dopaminergic mechanisms.
• These findings support the potential of FDA 27F and FDA 40 as research tools for dopaminergic system investigations.